ArticleFrontiers in immunology2025

Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.

Ning Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.